Get the Stockscreener App
3.73
1.58%
-0.06
After Hours:
3.91
0.18
+4.83%
Bicycle Therapeutics Plc Adr stock is traded at $3.73, with a volume of 472.23K.
It is down -1.58% in the last 24 hours and down -13.26% over the past month.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
See More
Previous Close:
$3.79
Open:
$3.75
24h Volume:
472.23K
Relative Volume:
1.32
Market Cap:
$261.07M
Revenue:
$63.39M
Net Income/Loss:
$-219.51M
P/E Ratio:
-1.1792
EPS:
-3.1631
Net Cash Flow:
$-231.83M
1W Performance:
+1.36%
1M Performance:
-13.26%
6M Performance:
-23.88%
1Y Performance:
-53.37%
1-Day Range:
$3.68
$3.805
1-Week Range:
$3.3301
$4.0386
52-Week Range:
$3.3301
$9.1592
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Name
Bicycle Therapeutics Plc Adr
Sector
Industry
Phone
011441223261503
Address
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
3.73 | 257.92M | 63.39M | -219.51M | -231.83M | -3.1631 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Hold |
| Oct-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-08-24 | Initiated | Stephens | Equal-Weight |
| Sep-06-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-11-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Aug-31-22 | Initiated | Cowen | Outperform |
| Jul-28-22 | Initiated | Barclays | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Apr-13-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Apr-07-22 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-14-22 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | SVB Leerink | Outperform |
| Dec-09-21 | Initiated | Needham | Buy |
| Sep-30-21 | Initiated | B. Riley Securities | Buy |
| Apr-20-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-12-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-20 | Initiated | Oppenheimer | Outperform |
| Apr-17-20 | Initiated | H.C. Wainwright | Buy |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Sep-11-19 | Upgrade | Goldman | Neutral → Buy |
| Jun-17-19 | Initiated | Canaccord Genuity | Buy |
| Jun-17-19 | Initiated | Goldman | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
| Jun-17-19 | Initiated | Piper Jaffray | Overweight |
View All
Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News
Non-operating income (total) of Bicycle Therapeutics Plc Sponsored ADR – HAN:50BA - TradingView
Bicycle Therapeutics plcADR Peer Comparison – Compare with Others - Value Research
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Renaissance Technologies LLC Buys 412,700 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz - The National Law Review
Bicycle Therapeutics (BCYC) Earnings Date and Reports 2026 - MarketBeat
Siren L.L.C. Trims Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
ETFs Investing in Bicycle Therapeutics Plc Sponsored ADR Stocks - TradingView
Tarsus Pharmaceuticals (TARS) moves 7.5% higher: Will this strength last? - MSN
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last? - Yahoo Finance
Price to earnings forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Enterprise value to EBIT forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Bicycle Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:BCYC) - TradingView
Price to sales forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
50BA Forecast — Price Target — Prediction for 2027 - TradingView
Bicycle Therapeutics shareholders approve all proposals at annual general meeting - Investing.com South Africa
BCYC - Finviz
Bicycle Therapeutics’ SWOT analysis: stock navigates trial delays - Investing.com
After plunging 20.2% in 4 weeks, here's why the trend might reverse for Bicycle Therapeutics (BCYC) - MSN
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Sees Significant Increase in Short Interest - MarketBeat
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - ChartMill
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bicycle Therapeutics (BCYC) loses 19.0% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bicycle Therapeutics (BCYC) schedules 2026 AGM with director, pay and auditor votes - Stock Titan
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
Bicycle Therapeutics doses first patient in pancreatic cancer trial By Investing.com - Investing.com South Africa
Bicycle Therapeutics doses first patient in pancreatic cancer trial - Investing.com
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares of Stock - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC) - Yahoo Finance
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Bicycle Therapeutics (BCYC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift - Investing.com
Bicycle Therapeutics announces leadership changes for next phase - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - PR Newswire
Investigation Alert: Bicycle Therapeutics plc (BCYC) Under ScrutinyContact Levi & Korsinsky for Details - ACCESS Newswire
BCYC: Q3 2025 featured higher R&D costs, a $59.1M net loss, and strong cash reserves supporting clinical progress - TradingView
Bicycle Therapeutics (BCYC) Stock Price, News & Analysis - MarketBeat
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com
BCYC: Cost realignment and pipeline progress extend financial runway into 2028 amid higher R&D spend - TradingView
BCYC: Q1 2025 net loss widened to $60.8M on higher R&D, with $793M cash to fund near-term operations - TradingView
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com
Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com
Bicycle Therapeutics CEO Lee sells shares worth $172,952 - Investing.com
Bicycle therapeutics executive sells shares worth over $21k - Investing.com
Europe Peptide Drug Conjugates Market Size & Outlook, 2030 - Grand View Research
Bicycle Therapeutics Plc Adr Stock (BCYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bicycle Therapeutics Plc Adr Stock (BCYC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Skynner Michael | CHIEF SCIENTIFIC OFFICER |
Oct 02 '26 |
Sale |
3.47 |
1,942 |
6,739 |
155,229 |
| Skynner Michael | CHIEF SCIENTIFIC OFFICER |
Oct 05 '26 |
Sale |
3.57 |
503 |
1,796 |
154,726 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Oct 02 '26 |
Sale |
3.47 |
1,572 |
5,455 |
92,803 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Oct 05 '26 |
Sale |
3.57 |
242 |
864 |
92,561 |
| Perry Jennifer Scott | Chief Operating Officer |
Oct 02 '26 |
Sale |
3.47 |
1,094 |
3,796 |
89,958 |
| Perry Jennifer Scott | Chief Operating Officer |
Oct 05 '26 |
Sale |
3.74 |
406 |
1,517 |
89,552 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Oct 02 '26 |
Sale |
3.47 |
6,167 |
21,399 |
597,504 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Oct 05 '26 |
Sale |
3.57 |
1,638 |
5,848 |
595,866 |
| Thompson Travis Alvin | Chief Financial Officer |
Oct 02 '26 |
Sale |
3.47 |
893 |
3,099 |
64,528 |
| Thompson Travis Alvin | Chief Financial Officer |
Oct 05 '26 |
Sale |
3.57 |
79 |
282 |
64,449 |
0.50%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):